Albert Labs International Corp.

ABRT

CA0127841041

Biotechnology & Medical Research

End-of-day quote Canadian Securities Exchange Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
0.015 ^CAD	+50.00%		+50.00%	+50.00%

2023	Albert Labs International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Albert Labs International Corp. Appoints Shabir Hasham to Its Board of Directors	CI

Albert Labs International Corp. announced that it has received CAD 0.3 million in funding

February 23, 2023

On February 24, 2023, Albert Labs International Corp. closed the transaction.

Latest news about Albert Labs International Corp.

Albert Labs International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Albert Labs International Corp. Appoints Shabir Hasham to Its Board of Directors	23-10-18	CI
Albert Labs International Corp. Announces Resignation of Michael Raymont as Board of Directors	23-09-05	CI
Albert Labs International Corp. Announces CEO Changes	23-09-05	CI
Albert Labs International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Albert Labs International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-07	CI
Albert Labs International Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-02	CI
Albert Labs International Corp. Auditor Raises 'Going Concern' Doubt	23-06-01	CI
Albert Labs International Corp. Announces Preliminary Acceptance of 35 Novel Innovative Claims	23-05-02	CI
Albert Labs International Corp. announced that it expects to receive CAD 3 million in funding	23-04-23	CI
Albert Labs International Corp. announced that it expects to receive CAD 0.83 million in funding from Cantheon Capital	23-03-22	CI
Albert Labs International Corp. announced that it has received CAD 0.3 million in funding	23-02-23	CI
Albert Labs International Corp. announced that it expects to receive CAD 0.3 million in funding	23-02-12	CI
Albert Labs International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
Albert Labs International Corp. announced that it expects to receive CAD 3 million in funding	22-11-23	CI
Albert Labs Signs Letter of Intent with Ingen CRO for First In-Human Clinical Studies	22-11-17	CI
Albert Labs Files New International PCT Patent Application for Scalable API Manufacturing	22-10-20	CI
Albert Labs International Corp. Announces the Appointment of Mike Thompson MBE and Katie Shelton-Innes to Its Board	22-07-11	CI
Albert Labs International Corp. Auditor Raises 'Going Concern' Doubt	22-06-08	CI
Albert Labs International Corp. Grants Health Canada License	22-05-16	CI
Albert Labs International Corp.' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies	22-05-12	CI
Albert Labs International Corp. Announces Board Appointments	22-04-26	CI
Albert Labs International Corp. Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia	22-03-30	CI
Albert Labs International Corp. Auditor Raises 'Going Concern' Doubt	22-03-14	CI
Albert Labs Inc. completed the acquisition of ME Resource Corp. in a reverse merger transaction.	22-03-09	CI

Chart Albert Labs International Corp.

Duration

Period

More charts

Albert Labs International Corp. is a Canada-based pharmaceutical drug development company. The Company is focused on active compounds in the treatment of mental health and providing rapid access to effective prescription medicines for people suffering from mental health disorders. The Company operates primarily in one business segment: research and development of drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs. The Company also focuses on developing solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE). The Company's first drug target, KRN-101, is a potential solution for cancer-related anxiety. KRN-101 is derived from natural psilocybin mycelium. Through collaborations with research institutions, hospital centers and government agencies, the Company uses existing clinical infrastructure to deliver and improve patient access to its treatment.

Sector

Biotechnology & Medical Research

Calendar

2024-05-26 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALBERT LABS INTERNATIONAL CORP.	+50.00%	815K
IQVIA HOLDINGS INC.	+1.77%	42.75B
LONZA GROUP AG	+47.70%	41.61B
MODERNA, INC.	+12.24%	41.34B
CELLTRION, INC.	-8.83%	26.59B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.35%	11B